In 1999, bladder cancer was newly diagnosed in

Size: px
Start display at page:

Download "In 1999, bladder cancer was newly diagnosed in"

Transcription

1 REVIEW INTRAVESICAL THERAPY FOR BLADDER CANCER ASHISH M. KAMAT AND DONALD L. LAMM In 1999, bladder cancer was newly diagnosed in about 54,200 patients, and 12,100 patients died of this disease in the United States. Despite an increase in the incidence of bladder cancer, mortality rates have declined by 8% between 1980 and The 5-year relative survival rate for patients with superficial bladder cancer is now about 95% largely because of improvements in intravesical therapy. Bacille Calmette-Guérin (BCG) immunotherapy, the most effective treatment and prophylaxis for superficial transitional cell carcinoma (TCC), decreases tumor recurrences, disease progression, and bladder cancer-specific mortality. Intravesical chemotherapy reduces short-term tumor recurrence rates but has failed to impact disease progression or survival. Newer immunologic and chemotherapeutic agents, advances in photodynamic therapy (PDT), and other measures to boost the efficacy of intravesical therapy for bladder cancer are promising. In this review, we highlight the advances in intravesical therapy in the management of TCC of the bladder. INTRAVESICAL IMMUNOTHERAPY From the Department of Urology, West Virginia University School of Medicine, Morgantown, West Virginia Reprint requests: Ashish M. Kamat, M.D., Department of Urology, Robert C. Byrd Health Sciences Center, West Virginia University, P.O. Box 9251, Medical Center Drive, Morgantown, WV Submitted: July 28, 1999, accepted (with revisions): September 23, 1999 BCG IMMUNOTHERAPY BCG is a live, attenuated vaccine that has emerged as the most effective agent for the treatment of superficial bladder cancer and was approved by the U.S. Food and Drug Administration (FDA) in 1990 for carcinoma in situ (CIS). BCG is a nonspecific immune system stimulant and requires an immunocompetent host to elicit its effects. 2 Of primary importance is the strong TH1 cellular immune response elicited by BCG. It activates macrophages, T lymphocytes, B lymphocytes, and BCG-activated killer cells. It stimulates lymphokine and interferon production and enhances natural killer cell activity. Recent data suggest that BCG might also exert its effect through the nitric oxide pathway. 3 Table I summarizes six studies showing a reduction of tumor recurrence from an average of 67% in controls to 29% with BCG. 4 9 In Lamm s study, 4 the mean time to recurrence increased from 24 to 48 months (P 0.01). Herr et al. 5 found a prolongation in the time to muscle invasion or metastasis with a reduction in mortality from 32% to 14% with BCG. Cystectomy was required in 42% of controls compared with 26% with BCG treatment, and the median time to cystectomy increased from 8 months (control) to 24 months (BCG). 10 In a subsequent report with 3 years additional follow-up, cancer deaths were reduced from 37% to 12% (P 0.01). 6 Pagano et al. 7 studied 133 randomized patients, and stage progression to T2 or higher occurred in 17% of controls versus 4% of those treated with BCG (P 0.001). Long-term follow-up studies have frequently demonstrated prolonged protection from tumor recurrence and reduction in tumor progression and mortality. The observed reduction in tumor recurrence ranges from 20% to 65%, with an average benefit of 40%, and the mean rate of progression is reduced from 28% in controls to 14% in those receiving BCG. 11 The superiority of BCG is most evident in the treatment of patients with CIS. An analysis of data from six prospective Phase II trials found a complete remission in 76% of BCG-treated patients. Importantly, the cystectomy rate was only 11% in responders versus 55% in the nonresponders (P ), and the time to cystectomy was increased from 31 to 74 months. 12 With optimal BCG immunotherapy, the complete response (CR) rate can be increased to 87%. 13 Residual CIS at the 3-month evaluation is not necessarily an indication for cystectomy or change in treatment. In the SouthWest Oncology Group study, the CR rate increased from 58% to 69% between 3 and 6 months without additional BCG. With three additional weekly BCG instillations, the CR rate increased from 55% to 84% at 6 months (P 0.01). 14 Herr et al. 10 reported that 32% of patients showing the presence of disease at 3 months after a 6-week course of BCG proceeded to a disease-free state by 2000, ELSEVIER SCIENCE INC. UROLOGY 55: , /00/$20.00 ALL RIGHTS RESERVED PII S (99)00463-X 161

2 Investigators TABLE I. Comparison of recurrence after TURBT alone vs. after BCG therapy Total Control TURBT Alone Recurrence Treatment BCG Therapy Recurrence P Value Lamm, (52) 30 6 (20) Herr et al., (95) (42) Herr et al., (100) 23 8 (35) Pagano et al., (83) (26) Melekos et al., (59) (32) 0.02 Krege et al., (46) (26) 0.01 Total (67) (29) KEY: TURBT transurethral resection of bladder tumor; BCG bacille Calmette-Guérin. Numbers in parentheses are percentages. 6 months. The response to BCG at 6 months can be used as a predictor of prognosis, with the number of patients developing progressive disease being significantly higher among the nonresponders. 15 Intravesical BCG can be used to treat CIS involving the prostatic urethral mucosa or prostatic ducts in the absence of stromal invasion. Intravesical BCG is not recommended for the treatment of muscle invasive disease. In a report of 13 patients with Stage T2 or higher bladder cancer treated with BCG, only 1 of 13 was disease free; 10 of 13 patients developed systemic disease and 7 patients died of metastases. 16 Although most accept that a single 6-week course of BCG is suboptimal, maintenance therapy has been controversial. Single monthly or quarterly BCG instillations are not superior to standard induction. 17 Kavoussi et al. 18 demonstrated that a second 6-week course of BCG could increase the efficacy from 36% to 65% in those treated prophylactically and from 37% to 71% for those treated for CIS (overall increase in response from 37.5% to 59.6%). Lamm et al. 19 have proposed an alternative 6 3 regimen that is superior to the 6 6 regimen. Patients receive a 6-week induction course of BCG and then three weekly instillations at 3 and 6 months and every 6 months thereafter for 3 years. With administration of three weekly BCG treatments 6 weeks after induction, 87% of patients with CIS had a CR and 83% of patients with CIS or rapidly recurring Ta or T1 TCC remained tumor free. Urinary cytokines peak in most patients after the initial sixth BCG installation, but patients previously exposed to BCG induction have optimal stimulation at 3 weeks, and continued BCG administration suppresses immune response and increases toxicity. Many patients in whom the 6 6 regimen failed may have received too much rather than too little BCG. To further reduce tumor recurrence, high doses of vitamins A, B 6, C, and E versus recommended daily allowances were studied. High-dose vitamins significantly reduced tumor recurrence, with 5-year estimates of tumor recurrence of 91% in the recommended daily allowance arm and 41% in the megadose arm. 20 BCG is generally well tolerated, although symptoms of cystitis do occur in up to 90% of patients. 21 The BCG dose can be reduced to one third, one tenth, one thirtieth, or even one one-hundredth as needed to prevent side effects. Isoniazid 300 mg daily relieves symptoms but prophylactic isoniazid is not advisable, since it can decrease the immune response to BCG in animal models. 22 BCG sepsis has been observed in approximately 0.4% of patients. The addition of prednisolone reproducibly improves survival in the animal model of BCG sepsis. 23 There is no evidence that BCG therapy is contraindicated in patients with vesicoureteral reflux. 24 BCG should not be given to immunocompromised patients or after a traumatic catheterization. OTHER IMMUNOTHERAPEUTIC AGENTS Interferons. Interferons are host-produced glycoproteins that mediate host immune responses in a dose-dependent fashion. 25 Torti et al. 26 reported a 25% CR in 16 patients with recurrent papillary TCC and a 32% CR and 26% partial response (persistent positive cytologic findings) in 19 patients with refractory CIS. Adverse reactions after intravesical interferon-alpha therapy are mild and include flu-like symptoms. In a recent review, Belldegrun et al. 27 concluded that recombinant interferon-alpha has an important role in the treatment of superficial TCC, particularly as secondline therapy after failure of BCG or chemotherapy and that it may have synergistic effects when combined with chemotherapy or BCG. Keyhole Limpet Hemocyanin. Keyhole limpet hemocyanin (KLH), a highly antigenic respiratory pigment of the mollusc Megathuria crenulata, is a nonspecific immune stimulator. Lamm et al. 28 reported a CR in 45% of patients and a partial response in 21% of patients with KLH for 6 weeks. The best responders were patients with CIS: 58% had a CR. Jurincic et al. 29 reported that KLH (14% 162 UROLOGY 55 (2), 2000

3 recurrence) was better than mitomycin (39.1% recurrence) in the prevention of recurrent superficial TCC (P 0.05). Flamm et al. 30 reported no difference in efficacy between KLH and ethoglucid. The advantage of KLH is its apparent lack of toxicity. Bropirimine. Bropirimine is a low-molecularweight immunomodulator with a wide spectrum of immune stimulating activity. Sarosdy et al. 31 reported a 52% CR in patients treated for residual disease. The best responders were those without prior intravesical therapy; of these, 70% had a CR. Despite demonstrated antitumor activity and the advantage of oral administration, bropirimine is no longer available in the United States. INTRAVESICAL CHEMOTHERAPY Intravesical chemotherapy became popular in the 1960s when thiotepa was shown to reduce tumor recurrence and eliminate one third of papillary tumors. 32 Unlike systemic chemotherapy, responses to topical chemotherapy are proportional to the drug concentration rather than the drug dose. 33 Responses are also dependent on the duration of exposure, which is short and limited by bladder capacity. Cytotoxic drugs are active against DNA in rapidly dividing cells. The drug is administered by way of a urethral catheter and left in the bladder for varying amounts of time. Although some urologists have the patient lie prone for 15 minutes to ensure contact of the drug with the urothelium at the dome, animal studies have suggested that this may not be necessary. 34 Table II summarizes several controlled studies that show the effect of intravesical chemotherapy on recurrence in patients undergoing transurethral resection of bladder tumor. MITOMYCIN C Mitomycin C is an antibiotic chemotherapeutic agent that causes cross-linking of DNA and inhibition of DNA synthesis. In treatment of Stage Ta and T1 disease, the CR averages 36% and the decrease in recurrence ranges from 19% to 42%. A single, immediate instillation of mitomycin C significantly decreases early tumor recurrence, but this benefit decreases with long-term follow-up, suggesting that mitomycin C does not impact the biology of low-risk bladder cancer. 35 Most mitomycin C instillation protocols have used 20 to 60 mg weekly for 6 to 8 weeks. Maintenance therapy has been unsuccessful, and evidence suggests that prolonged courses are not superior to short courses. 36 Mitomycin C is very expensive, and controlled trials have failed to show improved efficacy when compared with other intravesical chemotherapies. 37 Because of its high molecular weight, the incidence of systemic side effects is low. The major adverse effect of intravesical mitomycin C is chemical cystitis, which occurs in up to 41% of patients. In one series, decreased bladder capacity was observed to be as high as 22%, with 2 of 76 patients requiring cystectomy for severe bladder contracture. 38 Facial and palmar skin rash, palmar desquamation, and eosinophilic cystitis are also seen. Patients should be advised to avoid contact with their urine after instillation. THIOTEPA Thiotepa, an aziridine with alkylating activity, is the only intravesical chemotherapy specifically approved by the FDA for the treatment of papillary TCC. Thiotepa is effective in the treatment of residual tumor or CIS, resulting in a CR in one third of the patients. As a prophylactic agent, 6 of 11 randomized controlled studies demonstrated a statistically significant reduction in tumor recurrence. 11 The decrease in the percentage of recurrence averages 16%, with a range of 12% to 41%. If we eliminate the large Medical Research Council (MRC) study that used a dilute concentration (30 mg/60 ml) from Table II, the advantage of thiotepa is as high as those of newer, more expensive, chemotherapeutic agents. As with other chemotherapeutic agents, protocols using early administration have shown better results, and multiple treatments have no added benefit. Thiotepa is generally well tolerated. The major adverse effect of thiotepa is myelosuppression due to systemic absorption. The incidence of leukopenia ranges from 8% to 54% and that of thrombocytopenia from 3% to 31%. 39 Recent tumor resection, extensive tumor, or concurrent cystitis can markedly increase absorption. DOXORUBICIN Doxorubicin disrupts the cell by several mechanisms, including inactivation of DNA topoisomerase II and production of activated oxygen radicals. As seen in Table II, doxorubicin reduces tumor recurrence compared with surgery alone by an average of 16%. Again, the maximal benefit in reported controlled prophylaxis studies occurred with a single, early postoperative instillation, 40 and maintenance therapy did not provide any added benefit. Evidence from work in our laboratory suggests that the efficacy of doxorubicin may be enhanced by simultaneous administration of oral quinolone antibiotics. 41 The primary side effect seen with doxorubicin is chemical cystitis, causing symptoms of dysuria, frequency, and urgency in up to 50% of patients. EPIRUBICIN Epirubcin (4 -epidoxorubicin) is an epimer of doxorubicin. A recent trial demonstrated that a single dose of epirubicin given intravesically im- UROLOGY 55 (2),

4 TABLE II. Investigators Effect of intravesical chemotherapy on recurrence in controlled studies of patients undergoing transurethral resection of bladder tumor Total Control (TURBT) Control Recurrence Chemotherapy Treatment Recurrence Difference % Recurred P Value* Thiotepa Burnand et al., (97) (58) Byar and Blackar, (60) (47) Nocks et al., (64) (65) 1 NS Asahi et al., (41) (40) 1 NS Schulman et al., (69) (59) 10 NS Koontz et al., (66) (39) Zincke et al., (71) 30 9 (30) Prout et al., (76) (64) MRCI, (37) (40) 3 NS Netto et al., (80) 14 6 (43) 37 NS Hirao et al., (46) 45 7 (15) Total (61) (44) 17 Doxorubicin Niijima et al., (62) (45) Zincke et al., (71) (32) Kurth et al., (59) (35) Rubben et al., (61) (56) 5 NS Akaza et al., (33) (25) 8 NS Abrams et al., (89) (79) 10 NS Total (55) (39) 16 Mitomycin C Huland and Otto, (52) 48 5 (10) Niijima et al., (62) (57) 5 NS Kim and Lee, (82) (81) 1 NS Tolley et al., (60) (41) Krege et al., (46) (27) Solsona et al., (12) 57 6 (10) 2 NS Akaza et al., (33) (24) 9 NS Total (48) (36) 12 Epirubicin Oosterlinck et al., (41) (29) Melekos et al., (59) (40) 19 NS Igawa et al., (69) (60) 9 NS Raitanen et al., (90) (75) 15 NS Rajala et al., (60) (35) Total (51) (39) 12 KEY: TURBT transurethral resection of bladder tumor; NS not significant. Numbers in parentheses are percentages. *Pvalue as reported by the original investigators. Length of follow-up and risk factors vary from study to study; therefore, statistical comparisons, other than those reported by the original investigators, were not appropriate and thus are not reported. Averages are presented for interest only. mediately after tumor resection was safe and significantly decreased tumor recurrence from 60% in those with resection alone to 34% in those treated with epirubicin. 42 The average benefit over transurethral resection of bladder tumor is 12% (Table II). As with other chemotherapeutic agents, recent studies have shown that maintenance instillation of epirubicin does not have any added benefit. 43 Epirubicin is not, at the time of writing, available in the United States, but approval for lung cancer has been sought. VALRUBICIN The FDA recently approved valrubicin for the treatment of BCG refractory CIS. Although valrubicin does not bind strongly to DNA, a principal mechanism of its action mediated by valrubicin metabolites is interference with the normal DNA 164 UROLOGY 55 (2), 2000

5 breaking-resealing action of DNA topoisomerase II. Greenberg et al. 44 demonstrated that six weekly intravesical doses of valrubicin resulted in a CR in 13 patients with superficial TCC. In a study of 87 patients with BCG refractory CIS who received six weekly instillations of 800 mg of valrubicin, a CR, as documented by bladder biopsies and cytologic examination, was seen in 21% of patients at a median follow-up of 18 months. 45 Patients should be informed that valrubicin has been shown to induce CRs in only about 1 in 5 patients and that delaying cystectomy could lead to the development of metastatic bladder cancer. It must be remembered that BCG refractory CIS is a dangerous disease, and cystectomy is generally curative. However, valrubicin is appropriate when other comorbid factors make the patient a poor risk for radical cystectomy. PHOTODYNAMIC THERAPY PDT involves intravenous administration of a photosensitizer such as Photofrin (sodium porfimer), which is a mixture of hematoporphyrinderived oligomers. When the photosensitizer is activated by laser light, selective tumor kill occurs by way of direct superoxide radical-mediated cytotoxicity, vascular endothelial damage, and a local inflammatory response. Several investigators have reported the effectiveness of PDT in the treatment of patients with recurrent superficial bladder cancer, with complete and partial response rates of 41% and 39%, respectively. 46 In 58 patients with resistant TCC, including Ta, T1, and refractory CIS of the urinary bladder reported by Nseyo et al., 47 the CR rate was 84% and 75% for residual resistant papillary TCC and refractory CIS, respectively; and 90% of patients treated prophylactically were without recurrence at 3 months. PDT treatment induces dose-related symptoms of cystitis. The most severe adverse reaction is permanent bladder contracture, which has been reported in 10% of patients. To avoid skin photosensitivity reactions, solar isolation is required for up to 6 weeks after Photofrin injection. Introduction of new photosensitizers and modifications of laser delivery techniques could lead to increased application of PDT in the near future. RECOMMENDATIONS INDICATIONS FOR INTRAVESICAL THERAPY At the time of presentation, most bladder tumors are superficial. The initial treatment is complete transurethral resection of the tumor. Intravesical therapy is not required in every patient. Low-grade Ta lesions have a low progression rate of 7% at 7 years and, in the absence of other risk factors, can be treated by resection alone. Even so, the European Organisation for Research and Treatment of Cancer (EORTC) reported a 12% reduction in tumor recurrence in such patients when treated with a single, early postoperative instillation of epirubicin. 48 Multifocal Ta disease is a relative indication for intravesical therapy. 49 Infrequent recurrences of low-grade Stage Ta disease can be treated with repeated resections; however, when recurrence is noted within 2 years, intravesical therapy should be considered. The conclusion that low-grade tumors are not a threat is erroneous; of all patients progressing to muscle invasive disease, 25% initially had grade 1, Stage Ta or T1 disease. 50 About 45% of newly diagnosed cancers are high-grade lesions and have a higher likelihood of recurrence and muscle invasion than similarly staged lowgrade lesions. 51 Long-term follow-up of patients with Stage T1, grade 3 TCC of the bladder treated locally is associated with a 52% progression rate and a median progression-free survival of 12.7 years. Up to 25% of patients will die of the cancer in the first 5 years and 10% of patients after 5 to 15 years. 52 Regardless of stage, grade 3 tumors recur in 70% of patients and have a 45% risk of progression at 3 years. Therefore, patients with grade 3 disease, regardless of tumor stage, should be offered intravesical therapy. Although grade is an important cofactor when considering the progression of T1 lesions, T1 tumors have an overall progression rate of 29% and warrant intravesical therapy. Other indications for adjuvant intravesical therapy include positive cytologic findings after transurethral resection of bladder tumor, recurrent tumors, extravesical urothelial tumors, and the presence of urothelial dysplasia. CIS should be considered a highly aggressive malignancy with a tendency to invade and metastasize. CIS has a high risk of disease progression and increases the risk of disease progression significantly to 65% at 5 years. 53 Hence, even a small focus of CIS is a definite indication for intravesical therapy. Intravesical immunotherapy has replaced cystectomy as the primary treatment for diffuse CIS, with CR rates reaching 84%. Prostatic urethral involvement with CIS carries a high risk of progression and must be treated aggressively. Transurethral resection is needed to carefully stage the disease and open the bladder neck so that BCG may bathe the prostatic urethra after intravesical instillation. Intravesical BCG immunotherapy has effectively eliminated the need for cystectomy in many of these patients. 13 The lower ureter and prostatic urethra remain relatively protected from the action of intravesical therapy, and continued surveillance in patients with high-grade TCC must include upper tract imaging and prostatic urethral biopsies at regular intervals. UROLOGY 55 (2),

6 CHOICE OF AGENT An analysis of practice patterns revealed that most community urologists (in Miami) used BCG to treat superficial TCC. 54 This is not true in Europe, where BCG is usually reserved for high-risk patients, with intravesical chemotherapy being the first choice of most urologists. We believe that intravesical BCG is the most effective treatment for superficial bladder cancer, especially CIS. Controlled comparative studies have shown that BCG is superior to thiotepa, doxorubicin, or mitomycin C. 55 As seen from Table II, thiotepa, doxorubicin, mitomycin C, epirubicin, and ethoglucid reduce the short-term recurrence rate by an average of 17%, 16%, 12%, 13%, and 31%, respectively. However, no consistent long-term reduction has been found in recurrence or reduction in disease progression or mortality. Prout et al. 56 demonstrated equal 5-year recurrence rates in patients treated with thiotepa versus surgery alone. Akaza et al. 57 reported a 6-year follow-up on a prospective randomized study and found no difference between chemotherapy and control with respect to the recurrence index or the mean time between recurrences. Controlled comparisons have also failed to demonstrate any difference among individual agents, with the exception of ethoglucid and doxorubicin. 58 The inability of intravesical chemotherapy studies to demonstrate any long-term benefit was taken as a challenge by investigators in the EORTC and MRC studies. In a combined metaanalysis of 2535 patients with Stage Ta and T1 TCC enrolled in six Phase III randomized trials, a significant (P 0.01) reduction in recurrence was seen in 1629 patients treated with thiotepa, teniposide, doxorubicin, epirubicin, mitomycin C, or oral pyridoxine compared with 906 patients treated with transurethral resection alone. Patients were monitored for up to 18 years (median 7.7). Although the overall reduction in tumor recurrence was only 7%, additional improvement might have been observed had control patients not later received intravesical therapy. 59 Unfortunately, no clear advantage of adjuvant treatment was shown with respect to progression, time to appearance of distant metastases, or duration of survival. Other studies of intravesical chemotherapy have also failed to demonstrate any effect on disease progression. In an analysis of 3899 patients enrolled in 22 randomized prospective controlled studies, Lamm et al. 60 found that progression occurred in 7.5% of those receiving intravesical chemotherapy and 6.9% of those treated by surgery alone. Intravesical chemotherapy has some efficacy in the management of CIS, with reported overall CR rates of 34%. BCG immunotherapy, on the other hand, does reduce long-term tumor recurrence, tumor progression, and mortality from superficial TCC. BCG immunotherapy reduces tumor recurrence by an average of 40% compared with the 14% average reduction with chemotherapy. The effect of immunotherapy is long lasting and includes a reduction in disease progression. The SouthWest Oncology Group reported that for patients with superficial tumors without CIS, the estimated probability of being disease free at 5 years was 17% after doxorubicin compared with 37% after BCG (P 0.015). The median time to treatment failure was 10.4 and 22.5 months, respectively. For patients with CIS, the CR probability estimate was 34% for doxorubicin and 70% for BCG (P 0.001); the median time to treatment failure was 5.1 and 39 months, respectively. The probability of being disease free at 5 years among the patients with CIS was 18% after treatment with doxorubicin and 45% after BCG therapy. 13 Melekos et al. 61 showed that BCG had a clear advantage with regard to prophylaxis of Stage T1 and high-grade tumors at a median follow-up of 33 months. Cookson et al. 62 reported that 91% of patients with high-risk Stage T1 TCC who received intravesical BCG immunotherapy were disease free at a mean follow-up of 59 months. Maintenance BCG has further improved the long-term protection from tumor recurrence in patients with Stage Ta and T1 disease. Furthermore, not all tumors that recur after BCG immunotherapy proceed to muscle invasion or metastasis, and some patients may be treated safely with repeated endoscopic resection and intravesical therapy, with cystectomy delayed until objective progression is evident. Such an approach can yield survival equal to that in patients treated with early cystectomy and may result in longer intervals of bladder preservation in a select subset of patients in whom BCG fails locally. 63 Several theories have been put forward to explain why BCG immunotherapy has an advantage over chemotherapy with respect to long-term recurrence and disease progression. BCG produces a mucosal infection that can persist for many months. The continued replication of organisms provides a longer duration of action than chemotherapy, which decreases in concentration rapidly after instillation and is finally removed with voiding 2 hours after instillation. Since intravesical chemotherapeutic agents are active against rapidly dividing tumor cells, the concept of preventing tumor recurrence with chemotherapy is illogical unless one assumes the presence of occult malignancy. Immunotherapy also has the potential to induce specific immunity to bladder tumors and prevent de novo tumor recurrence. Finally, BCG is able to penetrate deep within the detrusor muscle and has even been observed in pelvic lymph nodes after instillation; chemotherapy is dependent on simple diffusion and penetrates to the depths of tumor extension poorly. However, there appears to be one situation in which intravesical chemotherapy holds a clear ad- 166 UROLOGY 55 (2), 2000

7 vantage over BCG. As previously mentioned, a single dose of intravesical chemotherapy immediately after tumor resection is safe and significantly decreases tumor recurrence. This is probably due to the action of the agent against residual tumor cells and prevention of reimplantation of exfoliated tumor cells. 64 It must be remembered, however, that not only does immediate intravesical immunotherapy have no added benefit over resection alone, it can lead to devastating consequences, such as BCG sepsis. CONCLUSIONS The management of superficial bladder cancer has evolved during the past 15 years, concurrent with improved understanding of the biology of superficial TCC. BCG immunotherapy not only reduces recurrences of superficial TCC but also decreases stage progression, cystectomy rates, and disease-specific mortality. Controlled comparative studies have shown that BCG is superior to intravesical chemotherapy, especially in CIS where a CR is seen in more than 70% of patients and the 5-year disease-free interval averages 40%. We believe that BCG is superior to chemotherapy even in the treatment of patients with recurrent Stage Ta or T1 tumors. Our recommendation is to use a 6-week induction course of BCG followed by three weekly BCG instillations at 3 and 6 months and every 6 months thereafter for 3 years. Chemotherapy is appropriate for instillation at the time of surgery in an attempt to reduce recurrence or as a second-line therapy for patients in whom BCG immunotherapy has failed. Newer immunologic and chemotherapeutic agents, advances in PDT, and other measures to boost the efficacy of intravesical therapy for bladder cancer demonstrate potential, but much work remains to be done in these areas. REFERENCES 1. Cohen SM, and Johansson SL: Epidemiology and etiology of bladder cancer. Urol Clin North Am 19: , Ratliff TL, Gillen DP, and Catalona WJ: Requirement of thymus dependent immune response for BCG mediated antitumor activity. J Urol 137: , Jansson OT, Morcos E, Brundin L, et al: The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer. Br J Cancer 78: , Lamm DL: Bacillus Calmette-Guérin immunotherapy for bladder cancer. J Urol 134: 40 47, Herr HW, Pinsky CM, Whitmore WF Jr, et al: Experience with intravesical bacillus Calmette-Guérin therapy of superficial bladder tumors. Urology 25: , Herr HW: Transurethral resection and intravesical therapy of superficial bladder tumors. Urol Clin North Am 18: , Pagano F, Bassi P, Milani C, et al: Low dose BCG regimen in superficial bladder cancer therapy: is it effective? J Urol 146: 32 35, Melekos MD, Chionis H, Pantazakos A, et al: Intravesical bacillus Calmette-Guérin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. J Urol 149: , Krege S, Giani G, Meyer R, et al: A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guérin. J Urol 156: , Herr HW, Laudone VP, Badalament RA, et al: Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol 6: , Lamm DL: Long term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19: , De Jager R, Guinan P, Lamm D, et al: Long term complete remission in bladder carcinoma in situ with intravesical Tice bacillus Calmette Guérin overview analysis of six phase II clinical trials. Urology 38: , Lamm DL, Blumenstein BA, Crawford ED, et al: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional cell carcinoma of the bladder. N Engl J Med 325: , Lamm DL: BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology (Huntingt) 9: , Orsola A, Palou J, Xavier B, et al: Primary bladder carcinoma in situ: assessment of early BCG response as a prognostic factor. Eur Urol 33: , Rosenbaum RS, Park MC, and Fleischmann J: Intravesical bacille Calmette-Guérin therapy for muscle invasive bladder cancer. Urology 47: , Badalament RA, Herr HW, Wong GY, et al: A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol 5: , Kavoussi LR, Torrence RJ, Gillen DP, et al: Results of 6 weekly intravesical bacillus Calmette-Guérin instillations on the treatment of superficial bladder tumors. J Urol 139: , Lamm DL, Blumenstein B, Sarsody M, et al: Significant long-term patient benefits with BCG maintenance therapy: a South West Oncology Group study. J Urol 157: , Lamm DL, Riggs DR, Shriver JS, et al: Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 151: 21 26, Lamm DL, van der Meijden APM, Morales A, et al: Incidence and treatment of complications of bacillus Calmette- Guérin intravesical therapy in superficial bladder cancer. J Urol 147: , De Boer EC, Steerenberg PA, van der Meijden APM, et al: Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig. J Urol 148: , DeHaven JI, Traynelis C, Riggs DR, et al: Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guérin toxicity. J Urol 147: , Bohle A, Schuller J, Knipper A, et al: Bacillus Calmette- Guérin treatment and vesicorenal reflux. Eur Urol 17: , Glashan R: A randomized controlled study of intravesical -2b-interferon in carcinoma in situ of the bladder. J Urol 144: , Torti FM, Shortliffe LD, Williams RD, et al: Alpha-interferon in superficial bladder cancer: a northern California oncology group study. J Clin Oncol 6: , Belldegrun AS, Franklin JR, O Donnell MA, et al: Superficial bladder cancer: the role of interferon-alpha. J Urol 159: , Lamm DL, Morales A, Grossman HB, et al: Keyhole UROLOGY 55 (2),

8 limpet hemocyanin (KLH) immunotherapy of papillary and in situ transitional cell carcinoma of the bladder. A multicenter phase I-II clinical trial. J Urol 155: A1405, Jurincic CD, Engelmann U, Gasch J, et al: Immunotherapy in bladder cancer with keyhole limpet hemocyanin: a randomized study. J Urol 139: , Flamm J, Bucher A, Höltl W, et al: Recurrent superficial transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy: a prospective randomized trial. J Urol 144: , Sarosdy MF, Lowe BA, Schellhammer PF, et al: Bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology 48: 21 27, Lamm DL, and Griffith JG: Intravesical therapy: does it affect the natural history of bladder cancer? Semin Urol 10: 39 44, Walker MC, Masstera JR, Parris CN, et al: Intravesical chemotherapy in vitro studies on the relationship between dose and cytotoxicity. Urol Res 14: , Wientjes MG, Dalton JT, Badalament RA, et al: Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res 51: , Solsona E, Iborra I, Ricos JV, et al: Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 161: , Huland H, Klöppel G, Feddersen I, et al: Comparison of different schedules of cystostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. J Urol 144: 68 75, Lamm DL: Clinical evaluation of immunotherapy. Cancer Surv 31: , Kim HH, and Lee C: Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor. J Urol 139: 245A, Thrasher JB, and Crawford ED: Complications of intravesical chemotherapy. Urol Clin North Am 19: , Zincke H, Utz DC, Taylor WF, et al: Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double blind, controlled trial. J Urol 129: , Kamat AM, DeHaven JI, and Lamm DL: Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. Urology 54: 56 61, Rajala P, Liukkonen T, Raitanen M, et al: Transurethral resection with perioperative instillation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study Finnbladder III. J Urol 161: , Okamura K, Kinukawa T, Tsumura Y, et al, for the Nagoya University Urological Oncology Group: A randomized study of short- versus long-term intravesical epirubicin instillation for superficial bladder cancer. Eur Urol 33: , Greenberg RE, Bahnson RR, Wood D, et al: Initial report on intravesical administration of N- trifluoroacetyl adriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology 49: , Bahnson R, Brosman S, Dalkin B, et al: Effectiveness of valrubicin in patients with BCG-refractory carcinoma in situ of the bladder. J Urol 161: 171, Nseyo UO: Photodynamic therapy. Urol Clin North Am 19: , Nseyo UO, DeHaven J, Dougherty TJ, et al: Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience. J Clin Laser Med Surg 16: 61 68, Oosterlinck W, Kurth KH, Schröder F, et al, and the Members of the European Organization for Research and Treatment of Cancer Genitourinary Group: A prospective European organization for research and treatment of cancer genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single state Ta, T1 papillary carcinoma of the bladder. J Urol 149: , Abel PD: Follow-up of patients with superficial transitional cell carcinoma of the bladder: the case for a change in policy. Br J Urol 72: , Bostwick DG: Natural history of bladder cancer. J Cell Biochem 161: 31 38, Messing EM, Young TB, Hunt VB, et al: Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 45: , Herr HW: Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 80: , Vicente J, Laguna MP, Duarte D, et al: Carcinoma in situ as a prognostic factor for G3pT1 bladder tumours. Br J Urol 68: , Obek C, Shelfo SW, Korman HJ, et al: Intravesical therapy for transitional cell carcinoma of the bladder: the community practice. Urology 53: 82 87, Lamm DL, and Torti FM: Bladder cancer, CA Cancer J Clin 46: , Prout GR Jr, Koontz WW Jr, Coombs LJ, et al, for the National Bladder Cancer Collaborative Group: Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol 130: , Akaza H, Koiso K, Kotake T, et al, and the Japanese Urological Cancer Research Group for Adriamycin: Long term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother Pharmacol 30: 15 19, Kurth KH, Debruyne FJM, Senge T, et al, and the Members of the EORTC GU-Group: Adjuvant chemotherapy of superficial transitional cell carcinoma: an E.O.R.T.C. randomized trial comparing doxorubicin hydrochloride, ethoglucid, and TUR alone, in Schröder FH, and Richards B (Eds): EORTC Genitourinary Group Monograph 2, Part B: Superficial Bladder Tumors. New York, Alan R Liss, 1985, pp Pawinski A, Sylvester R, Kurth KH, et al: A combined analysis of EORTC/MRC randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol 156: , Lamm DL, Riggs DR, Traynelis CL, et al: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153: , Melekos MD, Chionis HA, Paranychianakis GS, et al: Intravesical 4 -epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. Cancer 72: , Cookson MS, and Sarosdy MF: Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette- Guérin therapy. J Urol 148: , Klein EA, Rogatko A, and Herr HW: Management of local bacillus Calmette-Guérin failures in superficial bladder cancer. J Urol 147: , Okuno H, Kakehi Y, Ozdemir E, et al: Association of in vitro growth potential of urinary exfoliated cells with tumor localization and intraluminal recurrence rates of urothelial cancers. J Urol 158: , UROLOGY 55 (2), 2000

Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.

Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.

More information

Efficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer

Efficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer S86 Efficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer Donald L. Lamm Department of Urology, West Virginia University, Morgantown In the United States, bladder cancer

More information

Management of Superficial Bladder Cancer Douglas S. Scherr, M.D.

Management of Superficial Bladder Cancer Douglas S. Scherr, M.D. Management of Superficial Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.

More information

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction

More information

The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study

The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study The Journal of International Medical Research 2009; 37: 1823 1830 The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary

More information

INTRAVESICAL THERAPY AND FOLLOW-UP OF SUPERFICIAL TRANSITIONAL CELL CARCINOMA OF THE BLADDER

INTRAVESICAL THERAPY AND FOLLOW-UP OF SUPERFICIAL TRANSITIONAL CELL CARCINOMA OF THE BLADDER Clinical Urology Brazilian Journal of Urology Official Journal of the Brazilian Society of Urology Vol. 26 (3): 242-249, May - June, 2000 INTRAVESICAL THERAPY AND FOLLOW-UP OF SUPERFICIAL TRANSITIONAL

More information

SUPERFICIAL BLADDER CANCER MANAGEMENT

SUPERFICIAL BLADDER CANCER MANAGEMENT A CME Webcast/TELECONFERENCE Case by Case: CRITICAL ISSUES IN SUPERFICIAL BLADDER CANCER MANAGEMENT An Interactive Case Format with Instant Audience Polling APRIL-MAY 2005 CME Program Slide Book Sponsored

More information

Protocol for BCG + maintenance, Donald L. Lamm, MD Last Updated Friday, 14 November 2008

Protocol for BCG + maintenance, Donald L. Lamm, MD Last Updated Friday, 14 November 2008 Protocol for BCG + maintenance, Donald L. Lamm, MD Last Updated Friday, 14 November 2008 {niftybox width=180px,float=right,textalign=left} update on the protocol: from Dr. Lamm's site: It is also true

More information

better time to first recurrence compared to no adjuvant treatment. 1 3 Previous large randomized clinical trials performed

better time to first recurrence compared to no adjuvant treatment. 1 3 Previous large randomized clinical trials performed 0022-5347/00/1634-1124/0 THE JOURNAL OF UROLOGY Vol. 163, 1124 1129, April 2000 Copyright 2000 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY

More information

Improving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression in Superficial Bladder Cancer

Improving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression in Superficial Bladder Cancer european urology supplements 5 (2006) 654 659 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Improving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression

More information

Radical Cystectomy Often Too Late? Yes, But...

Radical Cystectomy Often Too Late? Yes, But... european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer

More information

Effectiveness of A Single Immediate Mitomycin C Instillation in Patients with Low Risk Superficial Bladder Cancer: Short and Long-Term Follow-up

Effectiveness of A Single Immediate Mitomycin C Instillation in Patients with Low Risk Superficial Bladder Cancer: Short and Long-Term Follow-up Journal of the Egyptian Nat. Cancer Inst., Vol. 19, No. 2, June: 121-126, 2007 in Patients with Low Risk Superficial Bladder Cancer: Short and Long-Term Follow-up SAMIR EL-GHOBASHY, M.D.; TAREK R. EL-LEITHY,

More information

Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer

Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer International Journal of Urology (2011) 18, 439 443 doi: 10.1111/j.1442-2042.2011.02766.x Original Article: Clinical Investigationiju_2766 439..443 Clinical significance of immediate urine cytology after

More information

Contents of Online Supporting Information. etable 1. Study characteristics for trials of intravesical therapy vs. TURBT alone

Contents of Online Supporting Information. etable 1. Study characteristics for trials of intravesical therapy vs. TURBT alone Contents of Online Supporting Information etable 1. Study characteristics for trials of intravesical therapy vs. TURBT alone etable 2. Study characteristics of head to head trials of intravesical therapy

More information

Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk Non-muscle-invasive

Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk Non-muscle-invasive Jpn J Clin Oncol 2013;43(3)305 313 doi:10.1093/jjco/hys225 Advance Access Publication 9 January 2013 Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk

More information

Issues in the Management of High Risk Superficial Bladder Cancer

Issues in the Management of High Risk Superficial Bladder Cancer Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma

More information

Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC

Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC Intravesical Therapy 2010-When, with What, When to Stop Friday, April 9, 2010 Ralph de VereWhite, MD Director, UC Davis Cancer Center Associate Dean for Cancer Programs Professor, Department of Urolgoy

More information

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non Muscle-Invasive Bladder Cancer

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non Muscle-Invasive Bladder Cancer european urology supplements 8 (2009) 458 463 available at www.sciencedirect.com journal homepage: www.europeanurology.com Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned

More information

THE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER

THE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER THE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER Mihály Zoltán Attila 1, Rusu Cristian Bogdan 2, Mihály Orsolya Maria 3, Bolboacă Sorana Daniela 4, Bungărdean

More information

/05/ /0 Vol. 174, 86 92, July 2005 THE JOURNAL OF UROLOGY. Printed in U.S.A. Copyright 2005 by AMERICAN UROLOGICAL ASSOCIATION

/05/ /0 Vol. 174, 86 92, July 2005 THE JOURNAL OF UROLOGY. Printed in U.S.A. Copyright 2005 by AMERICAN UROLOGICAL ASSOCIATION 0022-5347/05/1741-0086/0 Vol. 174, 86 92, July 2005 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2005 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000162059.64886.1c BACILLUS CALMETTE-GUERIN

More information

european urology 52 (2007)

european urology 52 (2007) european urology 52 (2007) 1123 1130 available at www.sciencedirect.com journal homepage: www.europeanurology.com Urothelial Cancer Long-Term Intravesical Adjuvant Chemotherapy Further Reduces Recurrence

More information

The Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor

The Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor Original Article Japanese Journal of Clinical Oncology Advance Access published December 17, 2010 Jpn J Clin Oncol 2010 doi:10.1093/jjco/hyq228 The Clinical Impact of the Classification of Carcinoma In

More information

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.

More information

Kyung Won Seo, Byung Hoon Kim, Choal Hee Park, Chun Il Kim, Hyuk Soo Chang

Kyung Won Seo, Byung Hoon Kim, Choal Hee Park, Chun Il Kim, Hyuk Soo Chang www.kjurology.org DOI:.4/kju..5..65 Urological Oncology The Efficacy of the EORTC Scoring System and Risk Tables for the Prediction of Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer after

More information

Management of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS

Management of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS Management of High-Risk Non-Muscle Invasive Bladder Cancer Seth P. Lerner, MD, FACS Professor of Urology, Beth and Dave Swalm Chair in Urologic Oncology, Scott Department of Urology, Baylor College of

More information

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma

More information

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,

More information

Staging and Grading Last Updated Friday, 14 November 2008

Staging and Grading Last Updated Friday, 14 November 2008 Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty

More information

UC San Francisco UC San Francisco Previously Published Works

UC San Francisco UC San Francisco Previously Published Works UC San Francisco UC San Francisco Previously Published Works Title Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer

More information

BLADDER CANCER: PATIENT INFORMATION

BLADDER CANCER: PATIENT INFORMATION BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,

More information

Patient Risk Profiles: Prognostic Factors of Recurrence and Progression

Patient Risk Profiles: Prognostic Factors of Recurrence and Progression european urology supplements 5 (2006) 648 653 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Patient Risk Profiles: Prognostic Factors of Recurrence and Progression

More information

Beware the BCG Failures: A Review of One Institution's Results

Beware the BCG Failures: A Review of One Institution's Results European Urology European Urology 42 (2002) 542±546 Beware the BCG Failures: A Review of One Institution's Results C. Richard W. Lockyer a,*, James E.C. Sedgwick b, David A. Gillatt a a Bristol Urological

More information

EAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER

EAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,

More information

Bladder Cancer Guidelines

Bladder Cancer Guidelines Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder

More information

Pharmacologyonline 3: (2006)

Pharmacologyonline 3: (2006) INTRAVESICAL MISTLETOE EXTRACT FOR ADJUVANT TREATMENT OF SUPERFICIAL URINARY BLADDER CANCER P. Bühler 1, C. Leiber 1, M. Lucht 2, P. Wolf 1, U. Wetterauer 1, U. Elsässer-Beile 1 1 Department of Urology,

More information

MEDitorial March Bladder Cancer

MEDitorial March Bladder Cancer MEDitorial March 2010 Bladder Cancer Last month, my article addressed the issue of blood in the urine ( hematuria ). A concerning cause of hematuria is bladder cancer, a variably malignant tumor starting

More information

Reviewing Immunotherapy for Bladder Carcinoma In Situ

Reviewing Immunotherapy for Bladder Carcinoma In Situ Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy

More information

Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer

Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer Z. AKÇETIN 1, J. TODOROV 1, E. TÜZEL 1, D.G. ENGEHAUSEN 1, F.S. KRAUSE 1, R. SAUER 2, K.M. SCHROTT

More information

A Randomized Trial Comparing Intravesical Instillations of Mitoxantrone and Doxorubicin in Patients with Superficial Bladder Cancer

A Randomized Trial Comparing Intravesical Instillations of Mitoxantrone and Doxorubicin in Patients with Superficial Bladder Cancer Original Article 91 A Randomized Trial Comparing Intravesical Instillations of and Doxorubicin in Patients with Superficial Bladder Cancer Jen-Seng Huang, MD; Wen Hsiang Chen 1, MD; Cheng-Chia Lin 1, MD;

More information

IAUN Conference Dublin, January Helen Forristal Cancer Nurse Co- Ordinator Jonathan Borwell Bladder Cancer Clinical Nurse Specialist

IAUN Conference Dublin, January Helen Forristal Cancer Nurse Co- Ordinator Jonathan Borwell Bladder Cancer Clinical Nurse Specialist IAUN Conference Dublin, January 2014 Helen Forristal Cancer Nurse Co- Ordinator Jonathan Borwell Bladder Cancer Clinical Nurse Specialist Theoretical component Observation Supervised practice Assessment

More information

Non-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience. Paul Gellhaus Assistant Clinical Professor

Non-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience. Paul Gellhaus Assistant Clinical Professor Non-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience Paul Gellhaus Assistant Clinical Professor Iowa??? none Disclosures Caveats Dr. Michael O Donnell

More information

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction

More information

Intravesical Chemotherapy: An Update önew Trends and Perspectives

Intravesical Chemotherapy: An Update önew Trends and Perspectives EAU Update Series 1 (2003) 71 79 Intravesical Chemotherapy: An Update önew Trends and Perspectives A.G. van der Heijden, J.A. Witjes * Department of Urology, University Medical Center Nymegen, Geert Grooteplein

More information

Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer

Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer Patrick A. Cockerill, John J. Knoedler, Igor Frank, Robert Tarrell and Robert

More information

Citation International journal of urology (2. Right which has been published in final f

Citation International journal of urology (2.  Right which has been published in final f Title Novel constant-pressure irrigation of renal pelvic tumors after ipsila Nakamura, Kenji; Terada, Naoki; Sug Author(s) Toshinori; Matsui, Yoshiyuki; Imamu Kazutoshi; Kamba, Tomomi; Yoshimura Citation

More information

The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis

The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Bladder Cancer 2 (2016) 273 278 DOI 10.3233/BLC-160048 IOS Press Research Report 273 The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Ashish

More information

T1HG Bladder Cancer What is the Best Therapy?

T1HG Bladder Cancer What is the Best Therapy? T1HG Bladder Cancer What is the Best Therapy? Ashish M. Kamat, MD, MBBS, FACS Professor of Urology Director, Urologic Oncology Fellowship Guidelines for T1HG Bladder Cancer AUA Recommendation: BCG induction

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/21069

More information

EUROPEAN UROLOGY 56 (2009)

EUROPEAN UROLOGY 56 (2009) EUROPEAN UROLOGY 56 (2009) 247 256 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Bladder Cancer Editorial by Guido Dalbagni on pp. 257 258 of this issue

More information

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER 10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg

More information

Organ-sparing treatment of invasive transitional cell bladder carcinoma

Organ-sparing treatment of invasive transitional cell bladder carcinoma Journal of BUON 7: 241-245, 2002 2002 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Organ-sparing treatment of invasive transitional cell bladder carcinoma C. Damyanov, B. Tsingilev,

More information

MICHAEL A. O DONNELL,* JANICE KROHN AND WILLIAM C. DEWOLF

MICHAEL A. O DONNELL,* JANICE KROHN AND WILLIAM C. DEWOLF 0022-5347/01/1664-1300/0 THE JOURNAL OF UROLOGY Vol. 166, 1300 1305, October 2001 Copyright 2001 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. SALVAGE INTRAVESICAL THERAPY WITH INTERFERON-

More information

Urological Oncology INTRODUCTION. M Hammad Ather, Masooma Zaidi

Urological Oncology INTRODUCTION. M Hammad Ather, Masooma Zaidi Urological Oncology Predicting Recurrence and Progression in Non-Muscle- Invasive Bladder Cancer Using European Organization of Research and Treatment of Cancer Risk Tables M Hammad Ather, Masooma Zaidi

More information

Case by Case: Critical Issues in Superficial Bladder Cancer Management 5/24/05 13:46 1

Case by Case: Critical Issues in Superficial Bladder Cancer Management 5/24/05 13:46 1 Case by Case: Critical Issues in Superficial Bladder Cancer Management 5/24/05 13:46 1 Case Study 1 A 22-year-old man with a history of gross total painless hematuria: two times in two months, both after

More information

Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)

Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS) Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt European Association of Urology 2011 TABLE OF CONTENTS

More information

CAN INTRAVESICAL BACILLUS CALMETTE-GUÉRIN REDUCE RECURRENCE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER? A META-ANALYSIS OF RANDOMIZED TRIALS

CAN INTRAVESICAL BACILLUS CALMETTE-GUÉRIN REDUCE RECURRENCE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER? A META-ANALYSIS OF RANDOMIZED TRIALS ADULT UROLOGY CAN INTRAVESICAL BACILLUS CALMETTE-GUÉRIN REDUCE RECURRENCE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER? A META-ANALYSIS OF RANDOMIZED TRIALS RUI FA HAN AND JIAN GANG PAN ABSTRACT Objectives.

More information

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto Int J Clin Oncol (2013) 18:75 80 DOI 10.1007/s10147-011-0346-8 ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in

More information

Phase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer

Phase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer Phase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer K. Hendricksen,* E. B. Cornel, T. M. de Reijke, H. C. Arentsen, S. Chawla and J. A. Witjes

More information

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group

More information

Management of Difficult Cases of Non-Muscle Invasive Bladder Cancer

Management of Difficult Cases of Non-Muscle Invasive Bladder Cancer Management of Difficult Cases of Non-Muscle Invasive Bladder Cancer 1 Bladder Cancer Recurrence is common Progression is uncommon Progression is more important than recurrence There are indicators of recurrence

More information

A rational risk assessment for intravesical recurrence in primary low grade Ta bladder cancer: A retrospective analysis of 245 cases

A rational risk assessment for intravesical recurrence in primary low grade Ta bladder cancer: A retrospective analysis of 245 cases MOLECULAR AND CLINICAL ONCOLOGY 8: 785-790, 2018 A rational risk assessment for intravesical recurrence in primary low grade Ta bladder cancer: A retrospective analysis of 245 cases MASAKAZU AKITAKE 1,

More information

UROTHELIAL CELL CANCER

UROTHELIAL CELL CANCER UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute

More information

Carcinoma of the Urinary Bladder Histopathology

Carcinoma of the Urinary Bladder Histopathology Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family

More information

EAU Guidelines on the Diagnosis and Treatment of Urothelial Carcinoma in Situ

EAU Guidelines on the Diagnosis and Treatment of Urothelial Carcinoma in Situ European Urology European Urology 48 (2005) 363 371 EAU Guidelines EAU Guidelines on the Diagnosis and Treatment of Urothelial Carcinoma in Situ Adrian P.M. van der Meijden a, *, Richard Sylvester b, Willem

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 153 Effective Health Care Program Emerging Approaches to Diagnosis and Treatment of Non Muscle-Invasive Bladder Cancer Executive Summary Background Bladder cancer

More information

Symptoms of Bacillus Calmette-Guerin Cystitis in Bladder Cancer Patients according to Tuberculosis Sequelae by Chest Radiography

Symptoms of Bacillus Calmette-Guerin Cystitis in Bladder Cancer Patients according to Tuberculosis Sequelae by Chest Radiography Original Article ISSN 2465-8243(Print) / ISSN: 2465-8510(Online) https://doi.org/10.14777/uti.2017.12.1.42 Urogenit Tract Infect 2017;12(1):42-48 http://crossmark.crossref.org/dialog/?doi=10.14777/uti.2017.12.1.&domain=pdf&date_stamp=2017-04-25

More information

Intravesical Therapy for Urothelial Carcinoma of the Urinary Bladder: A Critical Review

Intravesical Therapy for Urothelial Carcinoma of the Urinary Bladder: A Critical Review Review Article Intravesical Therapy for Urothelial Bladder Carcinoma International Braz J Urol Vol. 35 (6): 640-651, November - December, 2009 doi: 10.1590/S1677-55382009000600002 Intravesical Therapy

More information

Theralase Provides Interim Data Analysis on Anti-Cancer Treatment for First Four Patients Treated

Theralase Provides Interim Data Analysis on Anti-Cancer Treatment for First Four Patients Treated Theralase Provides Interim Data Analysis on Anti-Cancer Treatment for First Four Patients Treated First Four Patients Treated with Company s Anti-Cancer Treatment Achieve Pre-Defined Primary, Secondary

More information

Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder

Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder Annals of Oncology : -5. 999. 999 Klimer Academic Publishers. Printed in the Netherlands. Original article Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/20460

More information

Generated by Foxit PDF Creator Foxit Software For evaluation only.

Generated by Foxit PDF Creator Foxit Software  For evaluation only. Tishreen University Journal for Research and Scientific Studies - Medical Sciences Series Vol. (3) No. (٣) 28 27 2 28 2 T3 T4 T2 T1 Ta TUR G3 G2 G1 * ٩ 27 2 Tishreen University Journal for Research and

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of electrically-stimulated intravesical chemotherapy for superficial bladder

More information

Bacillus Calmette Guérin and Bladder Cancer

Bacillus Calmette Guérin and Bladder Cancer Review Article Bacillus Calmette Guérin and Bladder Cancer Azad H.A. Razack, Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. Bladder cancer is the second most

More information

Bladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope

Bladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope Bladder Cancer Canada November 21st, 2018 Bladder Cancer 2018: A brighter light at the end of the cystoscope Chris Morash MD FRCSC Associate Professor, University of Ottawa Head, Urological Oncology Bladder

More information

Haematuria and Bladder Cancer

Haematuria and Bladder Cancer Haematuria and Bladder Cancer Dr Pardeep Kumar Consultant Urological Surgeon Haematuria 3 Haematuria Macroscopic vs Microscopic Painful vs Painless Concurrent abdo pain/urinary symptoms Previous testing?

More information

When to Integrate Surgery for Metatstatic Urothelial Cancers

When to Integrate Surgery for Metatstatic Urothelial Cancers When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male

More information

TREATMENT OF PATIENTS WITH SUPERFICIAL BLADDER CANCER STRATIFIED BY RISK GROUPS TREATED WITH LYOPHILIZED MOREAU-RIO DE JANEIRO BCG STRAIN

TREATMENT OF PATIENTS WITH SUPERFICIAL BLADDER CANCER STRATIFIED BY RISK GROUPS TREATED WITH LYOPHILIZED MOREAU-RIO DE JANEIRO BCG STRAIN Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology Vol. 28 (5): 426-436, September - October, 2002 TREATMENT OF PATIENTS WITH SUPERFICIAL BLADDER CANCER STRATIFIED

More information

Received May 20, 2011; Accepted June 30, DOI: /etm

Received May 20, 2011; Accepted June 30, DOI: /etm EXPERIMENTAL AND THERAPEUTIC MEDICINE 2: 901-905, 2011 Intravesical administration of pirarubicin against superficial bladder cancer: Relationship between tumor tissue concentration and exposure time in

More information

Panel: A Case-based Approach to the Management of Bladder Cancer

Panel: A Case-based Approach to the Management of Bladder Cancer Panel: A Case-based Approach to the Management of Bladder Cancer ~ Moderator: Robert Donohue, MD Panel: David C. Beyer, MD E. David Crawford, MD Donald L. Lamm, MD Paul D. Maroni, MD TCC Cases Robert E.

More information

European Urology 46 (2004) 65 72

European Urology 46 (2004) 65 72 European Urology European Urology 46 (2004) 65 72 Preliminary European Results of Local Microwave Hyperthermia and ChemotherapyTreatment in Intermediate or High Risk Superficial Transitional Cell Carcinoma

More information

A patient with recurrent bladder cancer presents with the following history:

A patient with recurrent bladder cancer presents with the following history: MP/H Quiz A patient with recurrent bladder cancer presents with the following history: 9/23/06 TURB 1/12/07 TURB 4/1/07 TURB 7/12/07 TURB 11/14/07 Non-invasive papillary transitional cell carcinoma from

More information

The Role of Bacillus Calmette-Guérin in the Treatment of Non Muscle-Invasive Bladder Cancer

The Role of Bacillus Calmette-Guérin in the Treatment of Non Muscle-Invasive Bladder Cancer EUROPEAN UROLOGY 57 (2010) 410 429 available at www.sciencedirect.com journal homepage: www.europeanurology.com Collaborative Review Bladder Cancer The Role of Bacillus Calmette-Guérin in the Treatment

More information

Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy

Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy European Urology European Urology 45 (2004) 292 296 Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy Barthold Ph. Schrier a, Maarten

More information

Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure

Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure Itay A. Sternberg, Guido Dalbagni,* Ling Y. Chen, Sherri M. Donat, Bernard H.

More information

Disclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility

Disclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility The Importance of Pathology? Seth P. Lerner, MD, FACS Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine Support for research Disclosures Photocure, Imalux,

More information

Partial Cystectomy for Invasive Bladder Cancer

Partial Cystectomy for Invasive Bladder Cancer European Urology Supplements European Urology Supplements 4 (2005) 67 71 Partial Cystectomy for Invasive Bladder Cancer Gerald H. Mickisch* Center of Operative Urology Bremen, Academic Hospital Bremen

More information

Mark Kowalski, Jacinthe Guindon, Louise Brazas, Celine Moore, Joycelyn Entwistle, Jeannick Cizeau, Michael A. S. Jewett* and Glen C.

Mark Kowalski, Jacinthe Guindon, Louise Brazas, Celine Moore, Joycelyn Entwistle, Jeannick Cizeau, Michael A. S. Jewett* and Glen C. A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-Guérin Mark Kowalski, Jacinthe Guindon,

More information

Index. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.

Index. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type. Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,

More information

Controversies in the management of Non-muscle invasive bladder cancer

Controversies in the management of Non-muscle invasive bladder cancer Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic

More information

Naim B Farah 1*, Rami Ghanem 2 and Mahmoud Amr 3

Naim B Farah 1*, Rami Ghanem 2 and Mahmoud Amr 3 Farah et al. BMC Urology 2014, 14:11 RESEARCH ARTICLE Open Access Treatment efficacy and tolerability of intravesical Bacillus Calmette-Guerin (BCG) - RIVM strain: induction and maintenance protocol in

More information

Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer

Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer Bladder Cancer 1 (2015) 65 72 DOI 10.3233/BLC-150008 IOS Press Research Report 65 Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer Ryan

More information

Original Article APMC-276

Original Article APMC-276 Original Article APMC-276 The Clinical Value of Immediate Second Transurethral Resection in Patients with High Grade Non-Muscle Inasive Bladder Cancer (HG-NMIBC) Syed Saleem Abbas Jafri, Zafar Iqbal Khan

More information

BCG LIVE (FOR INTRAVESICAL USE) TICE BCG

BCG LIVE (FOR INTRAVESICAL USE) TICE BCG BCG LIVE (FOR INTRAVESICAL USE) TICE BCG WARNING TICE BCG contains live, attenuated mycobacteria. Because of the potential risk for transmission, it should be prepared, handled, and disposed of as a biohazard

More information

WARNING. For intravesical use the entire vial is reconstituted with sterile saline. TICE BCG is viable upon reconstitution.

WARNING. For intravesical use the entire vial is reconstituted with sterile saline. TICE BCG is viable upon reconstitution. TICE BCG BCG Live For Intravesical Use WARNING TICE BCG contains live, attenuated mycobacteria. Because of the potential risk for transmission, it should be prepared, handled, and disposed of as a biohazard

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology

More information

Risk Adapted Treatment of Non-muscle Invasive Bladder Cancer. Eila C. Skinner, MD

Risk Adapted Treatment of Non-muscle Invasive Bladder Cancer. Eila C. Skinner, MD Risk Adapted Treatment of Non-muscle Invasive Bladder Cancer Eila C. Skinner, MD Professor, Department of Urology Stanford University SWIU Winter Meeting January, 2015 Goals Minimize treatment for patients

More information

Symptomatic Granulomatous Prostatitis following Bacillus Calmette-Guerin Immunotherapy for Bladder Cancer

Symptomatic Granulomatous Prostatitis following Bacillus Calmette-Guerin Immunotherapy for Bladder Cancer Symptomatic Granulomatous Prostatitis following Bacillus Calmette-Guerin Immunotherapy for Bladder Cancer M. A.Noor,S. R. Biyabani,J. Talatia ( Departments of Surgery (Section of Urology), The Aga Khan

More information

BJUI. Invasive T1 bladder cancer: indications and rationale for radical cystectomy

BJUI. Invasive T1 bladder cancer: indications and rationale for radical cystectomy 2008 The Authors; Journal compilation 2008 BJU International Mini-review Article INVASIVE T1 BLADDER CANCER: INDICATIONS AND RATIONALE FOR RADICAL CYSTECTOMY STEIN and PENSON BJUI BJU INTERNATIONAL Invasive

More information

Urological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim.

Urological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim. www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.7.457 Urological Oncology Multivariate Analysis of the Prognostic Significance of Resection Weight after Transurethral Resection of Bladder Tumor

More information